ASSOCIATION OF COAGULATION FACTORS WITH THE PRESENCE OF UNSTABLE ATHEROSCLEROTIC PLAQUES IN THE CORONARY ARTERIES

Objective. This study was devoted to examinationof some factors of blood coagulation (factor II, factor VII, factor XII, antithrombin III) in order to find their associations with biomarkers of endothelial dysfunction (endothelin 1, monocyticchemoattractant protein type 1, MCP-1, lipoprotein (a), LP (a), adhesive molecules sVCAM-1, asymmetric dimethylarginin, ADMA, homocysteine), inflammation (interleukins, IL-6, IL - 8, C-reactive protein, CRP) and with unstable atherosclerotic plaques in the coronary arteries in men with coronary atherosclerosis.

Material and methods. In 93 men with coronary atherosclerosis without acute coronary syndrome, blood coagulation factors concentrations (factor II, factor VII, factor XII, antithrombin III) were studied in the blood with goal to find their associations with biomarkers of endothelial dysfunction (endothelin 1, MCP-1, LP(a), adhesion molecules sVCAM-1, ADMA, homocysteine), of inflammation (IL-6, IL-8, CRP) and with the presence of unstable plaques in the coronary arteries.

Results. In men with unstable atherosclerotic plaques in the coronary arteries, the blood levels of factor VII and factor XII were 1.3 and 1.3 times higher, respectively, compared to men who had stable plaques in the coronary arteries. Correlation links between the blood levels of factor II and factor XII and the presence of unstable atherosclerotic plaques in the coronary arteries (r=0.239 and r=0.250, p <0.05, respectively) have been revealed, as well as between coagulation factors and blood levels of LP(a), sVCAM-1, IL-6 and CRP. Results of logistic regression analysis showed that the relative risk of present of unstable atherosclerotic plaques in the coronary arteries is associated with an elevated blood level of factor XII (OR=1.008, 95 % CI 1.000-1.017, p=0.048).

Conclusion. Our results indicate that elevated blood levels of the Hageman factor may be a new biomarker of probability of unstable atherosclerotic plaques presence in the coronary arteries.

1. Ragino YuI, Chernjavskii АM, Volkov АМ, et al. Factors and mechanisms of instability of atherosclerotic plaque. Novosibirsk: Science. 2008. р. 88. ISBN 978-5-02-023256-3.

2. Waksman R, Seruys PW. Handbook of the Vulnerable Plaque. London, 2004:1-48. ISBN 0-203-48989-6.

3. Ragino YuI, Chernjavskii АM, Polonskaya YaV, et al. Oxidative and endothelial dysfunctional biomarkers of instability of atherosclerotic plaques. Studies of the vascular wall and blood. Bulletin of experimental biology and medicine. 2012;153(3):308-13. doi:10.1007/s10517-012-1708-6.

4. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 2006;47(8 Suppl):13-8. doi:10,1016/j.jacc.2005.10.065.

5. Niccoli G, Liuzzo G, Montone RA, et al. Advances in mechanisms, imaging and management of the unstableplaque. Atherosclerosis. 2014;233(2):467-77. doi:10.1016/j.atherosclerosis.2014.01.036.

6. Fishbein MC. The vulnerable and unstableatherosclerotic plaque. Cardiovasc. Pathol. 2010;19(1):6-11. doi:10.1016/j.carpath.2008.08.004.

7. Ragino YuI, Chernjavskii АM, Volkov AM, et al. Factors and mechanisms of coronary atherosclerosis. Novosibirsk: Science. 2011. р. 168. ISBN 978-5-02-018975-1.

8. Jenny NC, Olson NC, Allison MA, et al. Multi-Ethnic Study of Atherosclerosis: Biomarkers of key biological pathways in cardiovascular disease. Glob Heart. 2016;11(3):327-36. doi:10,1016/j.gheart.2016.07.003.

9. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol. 2007;27:15-26. doi:10.1161/01.ATV.0000251503.35795.4f.

10. Cirillo P, Cali G, Golino P, et al. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal–regulated kinase activation. Circulation. 2004;109(23):2911-6. doi:10.1161/01.CIR.0000129312.43547.08.

11. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood. 2012;120(22):4296- 303. doi:10.1182/blood-2012-07-292094.

12. Nickel KF, Long AT, Fuchs TA, et al. Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler. Thromb. Vasc. Biol. 2017;37(1):13-20. doi:10.1161/ATVBAHA.116.308595.

13. Kenne E, Nickel KF, Long AT, et al. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J. Intern. Med. 2015;278(6):571-85. doi:10.1111/joim.12430.

14. Miller GJ, Ireland HA, Cooper JA, et al. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease. Journal of Thrombosis and Haemostasis. 2008;6(2):259-67. doi:10.1111/j.1538-7836.2007.02819.x.

15. Kuijpers MJ, van der Meijden PE, Feijge MA, et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arteriosclerosis, thrombosis, and vascular biology. 2014;34(8):1674-80. doi:10.1161/ATVBAHA.114.303315.